Table 4

Response to blinatumomab.

	All (N=23)	Control (N=6)	IVIG (N=17)	P
Achieved disease response to blinatumomab^a),b)	16 (80)	5 (83.3)	12 (85.7)	1
Proceeded to HSCT	14 (60.9)	5 (83.3)	9 (52.9)	0.34
Time to HSCT, days, median (range)	105 (58–289)	1 04 (64–129)	106 (58–289)	0.61
Proceeded to other line of therapy	4 (17.1)	1 (16.7)	3 (17.6)	-
Time to next therapy, days, median (range)	123 (108–608)	123 (123–123)	123 (108–608)	1
If MRD (+) disease, achieved MRD (-)^a),b)	N=15	N=5	N=10
If MRD (+) disease, achieved MRD (-)^a),b)	12 (80)	4 (80)	8 (80)	1
Time to response, days, median (range)	39.5 (29–83)	46.5 (32–83)	37 (29–85)	0.65
If relapsed/refractory disease, achieved CR^a)	N=5	N=1	N=4
If relapsed/refractory disease, achieved CR^a)	5 (100)	1 (100)	4 (100)	-
CR with MRD (+)	2 (40)	1 (100)	1 (25)	0.4
Time to result, days, median (range)	34 (30-89)	89	33 (30-35)	0.5

All values listed as N (%) unless otherwise noted.

^a)Excluding 3 patients who received blinatumomab for consolidation/maintenance therapy. ^b)One patient in the IVIG cohort achieved partial response, defined as 1–2 log reduction in BCR-ABL PCR.

Abbreviations: CR, complete response; HSCT, hematopoietic stem cell transplant; MRD, minimal residual disease.

Blood Res 2022;57:135~143 https://doi.org/10.5045/br.2022.2021163